Fluoxetine, 10 mg capsules 20 pcs

Pharmacotherapeutic group

Antidepressant

ATX code: N06AB03

Pharmacodynamics:

Blocks selectively the neuronal reuptake of serotonin (5NT) in the synapses of neurons of the central nervous system. Inhibition of serotonin reuptake leads to increased concentration of this neurotransmitter in the synaptic cleft enhances and prolongs its effect on postsynaptic receptor sites. In therapeutic doses, fluoxetine blocks serotonin uptake by human platelets. It is a weak antagonist of muscarinic histamine H1 adrenergic a1 and a2 receptors has little effect on dopamine reuptake. Causes reduction of obsessive-compulsive disorders as well as decreased appetite, which may lead to weight loss. It does not cause a sedative effect. It has practically no effect on cardio-vascular and other systems functions when administered in medium therapeutic doses.

Pharmacokinetics:

When taken orally the drug is well absorbed from the gastro-intestinal tract (up to 95% of the dose taken). Food use insignificantly inhibits absorption of fluoxetine. Maximum plasma concentrations are reached after 6-8 hours. Bioavailability of fluoxetine after oral administration is more than 60%. The drug accumulates well in tissues easily penetrates through the blood-brain barrier and binds to plasma proteins by more than 90%. The drug is metabolized in the liver by demethylation to the active metabolite norfluoxetine and a number of unidentified metabolites. Renal clearance of fluoxetine is 94-704 ml/min for norfluoxetine 60-336 ml/min. About 12% of the drug is excreted through the gastrointestinal tract. The half-life of fluoxetine is about 2-3 days for norfluoxetine – 7-9 days. In patients with hepatic impairment, the half-life of fluoxetine and norfluoxetine is prolonged. The drug is excreted with breast milk (up to 25% of the serum concentration).

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

Special Instructions

Contraindications

Side effects

Overdose

Similarities